PURPOSE: @entity13950 (EMP) is an oral cytotoxic agent that depolymerizes tubuline, a mechanism of action that has been revisited during the last decade. Because of its lack of haematological @entity137 and favourable tolerance profile, EMP is a good candidate for palliative chemotherapy. The aim of the study was to assess its tolerance and efficacy in @entity0 after failure with usual regimens. @entity1 AND METHODS: @entity1 with a life expectancy of at least 12 weeks and bi-dimensionally measurable disease having received at least 1 line of chemotherapy (including @entity6023 and/or @entity8253 ) for @entity0 ( @entity0 ) were eligible. EMP was given daily at a dose of 10 mg/kg until disease progression, unacceptable @entity137 or @entity1 refusal to continue chemotherapy. RESULTS: Forty @entity1 were included between June 1998 and December 1999. @entity1 had previously received one to eight chemotherapy regimens (median is two) for @entity0 . Twenty-two @entity1 (55%) had visceral involvement and eighteen @entity1 (45%) had osseous, chest wall or soft tissue metastases. Adverse events leading to early interruption of EMP were grade 2 @entity566 (n = 1), grade 2-3 @entity390 (n = 6), @entity1150 (n = 1), grade 3 @entity295 (n = 1). One @entity1 died at twenty-four weeks from @entity1151 , and another at fourteen weeks from unknown cause. Seven objective responses were observed (17.5%; 95% confidence interval (CI): 6%-30%). Median time to failure was 24 weeks (14-52+) in responding @entity1 . All objective responses but one were observed in @entity1 with visceral metastases. In 10 other @entity1 (25%), disease remained stable with a median time to failure of 27 weeks (16-50); 6 of these experienced a decrease of consumption of analgesics or an improvement of performance status. CONCLUSION: EMP is an active drug in @entity0 after failure with @entity6023 and @entity8253 , whose tolerance profile appears favourable.

Single-agent XXXX (EMP) is active in @entity0 after failure with @entity8253 and @entity6023 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity6023 :: ('MESH:D043823', 'Chemical') :: ['taxanes'] @entity0 :: ('MESH:D001943', 'Disease') :: ['advanced breast cancer', 'ABC'] @entity8253 :: ('MESH:D018943', 'Chemical') :: ['anthracyclines'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis'] @entity566 :: ('MESH:D006967', 'Disease') :: ['allergy'] @entity1151 :: ('MESH:D011655', 'Disease') :: ['pulmonary embolism'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep-vein thrombosis'] @entity13950 :: ('CHEBI:68643', 'Chemical') :: ['Estramustine phosphate']
@entity13950 :: (CHEBI:68643,Chemical) :: ['estramustine phosphate']
